[Application of tumor marker for immunotargeting therapy of cancer].
For many years, attempts have been made to utilize the monoclonal antibody against tumor markers for diagnostic purposes. On the other hand, studies with various form of immunoconjugate have demonstrated some therapeutic promise. In this paper, the ideal tumor marker for immunotargeting therapy will be discussed. Results of clinical trials of radioimmunoconjugates, immunotoxin and chemoimmunoconjugates will be reviewed and prospects of these new approaches for the treatment of cancer patients will be presented.
Yamaguchi
T
T
First Department of Surgery, Kyoto Prefectural University of Medicine.
Takahashi
T
T
Kitamura
K
K
Otsuji
E
E
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D006801:Humans; D018796:Immunoconjugates; D000922:Immunotoxins / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D000922:Immunotoxins